This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Migraine

A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study

Sponsored by PiLeJe

About this trial

Last updated 9 years ago

Study ID

PiL-Obs-AntMIG-014

Status

Completed

Type

Observational

Placebo

No

Accepting

18-75 Years
18 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 10 years ago

What is this trial about?

Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.

What are the participation requirements?

Yes

Inclusion Criteria

- to suffer from migraine with or without aura diagnosed according to the criteria of the International Classification of Headaches Disorders III (ICHD III 1.1 and 1.2)

- to suffer from migraine for more than one year

- to be less than 50 years old at migraine onset

- to have had at least two migraine attacks during the month before recruitment

No

Exclusion Criteria

- migraine with aura with motor symptoms (hemiplegic migraine)

- more than 15 migraine attacks per month

- abuse of painkillers defined as the use of paracetamol, aspirin and non-steroid anti-inflammatory drugs for more than 15 days per month over the last three months or the use of triptans, opioids and ergot-type medications for more than 10 days per month during the last three months

- prophylactic treatment taken for less than 3 months